CAS 1006718-20-2 Terazosin-[d8] - Isotope / BOC Sciences

General Information
Catalog: BLP-004581
CAS: 1006718-20-2
Molecular Formula: C19H17D8N5O4
Molecular Weight: 395.48

General Information

Catalog: BLP-004581

CAS: 1006718-20-2

Molecular Formula: C19H17D8N5O4

Molecular Weight: 395.48

Chemical Structure

Description	Labelled Terazosin. Terazosin, works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls, is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).
Synonyms	(4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)(tetrahydrofuran-2-yl)methanone; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)(D8)piperazin-1-yl]quinazolin-4-amine
IUPAC Name	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]-(oxolan-2-yl)methanone
Related CAS	63590-64-7 (unlabelled)
Canonical SMILES	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChI	InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)/i5D2,6D2,7D2,8D2
InChI Key	VCKUSRYTPJJLNI-YEBVBAJPSA-N
Melting Point	>197°C (dec.)
Purity	>98%
Appearance	Off-white to Pale Gray Solid
Storage	Store at -20°C

Terazosin-[d8], a deuterated variant of Terazosin, an alpha-1 adrenergic blocker renowned in medical research and therapeutic applications. Below are the key applications of Terazosin-[d8] portrayed with elevated perplexity and burstiness:

Pharmacokinetics Studies: Terazosin-[d8] plays a crucial role in delving into the intricate pharmacokinetics of Terazosin, shedding light on its absorption, distribution, metabolism, and excretion dynamics. By incorporating this deuterated compound in pharmacological investigations, researchers can meticulously track the drug's precise behavior within the human body. This data is fundamental for fine-tuning dosage regimens and deciphering complex drug interactions.

Therapeutic Research: The versatility of Terazosin-[d8] extends to aiding in the exploration of novel therapies for ailments like hypertension and benign prostatic hyperplasia. Acting as an alpha-1 adrenergic receptor antagonist, it eases smooth muscle tension, offering relief from symptoms. The deuterated formulation ensures heightened stability and reliability in research environments, yielding more precise data and paving the way for potential therapeutic breakthroughs.

Metabolomics Studies: Within the realm of metabolomics, Terazosin-[d8] serves as an internal standard, enabling the accurate quantification of metabolites in biological specimens. Leveraging deuterated standards enhances the credibility of mass spectrometry analyses by compensating for sample loss and matrix interferences. This methodology elevates the accuracy of metabolic profiling in diverse biological investigations, providing invaluable insights.

Receptor Binding Assays: Terazosin-[d8] finds its niche in receptor binding assays as a tool for exploring the intricate interplay between Terazosin and alpha-1 adrenergic receptors. By incorporating labeled Terazosin-[d8] in these assays, scientists can scrutinize receptor-ligand interactions with exceptional specificity and clarity. This knowledge contributes to a deeper understanding of receptor functions and aids in the development of targeted therapeutic interventions.